Global Biologics and Biosimilars Market Analysis and Forecast 2024-2030
Summary
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, The global Biologics and Biosimilars market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Biologics and Biosimilars segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Biologics and Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics and Biosimilars sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, The global Biologics and Biosimilars market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Biologics and Biosimilars segment by Company
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- United Laboratories
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Others
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Biologics and Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics and Biosimilars sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Biologics and Biosimilars Market by Type
1.2.1 Global Biologics and Biosimilars Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Biologics and Biosimilars Market by Application
1.3.1 Global Biologics and Biosimilars Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 BIOLOGICS AND BIOSIMILARS MARKET DYNAMICS
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 GLOBAL MARKET GROWTH PROSPECTS
3.1 Global Biologics and Biosimilars Revenue Estimates and Forecasts (2019-2030)
3.2 Global Biologics and Biosimilars Revenue by Region
3.2.1 Global Biologics and Biosimilars Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global Biologics and Biosimilars Revenue by Region (2019-2024)
3.2.3 Global Biologics and Biosimilars Revenue by Region (2025-2030)
3.2.4 Global Biologics and Biosimilars Revenue Market Share by Region (2019-2030)
3.3 Global Biologics and Biosimilars Sales Estimates and Forecasts 2019-2030
3.4 Global Biologics and Biosimilars Sales by Region
3.4.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global Biologics and Biosimilars Sales by Region (2019-2024)
3.4.3 Global Biologics and Biosimilars Sales by Region (2025-2030)
3.4.4 Global Biologics and Biosimilars Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
4.1 Global Biologics and Biosimilars Revenue by Manufacturers
4.1.1 Global Biologics and Biosimilars Revenue by Manufacturers (2019-2024)
4.1.2 Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global Biologics and Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global Biologics and Biosimilars Sales by Manufacturers
4.2.1 Global Biologics and Biosimilars Sales by Manufacturers (2019-2024)
4.2.2 Global Biologics and Biosimilars Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global Biologics and Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global Biologics and Biosimilars Sales Price by Manufacturers (2019-2024)
4.4 Global Biologics and Biosimilars Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Biologics and Biosimilars Manufacturers, Product Type & Application
4.7 Global Biologics and Biosimilars Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global Biologics and Biosimilars Market CR5 and HHI
4.8.2 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
5 BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
5.1 Global Biologics and Biosimilars Revenue by Type
5.1.1 Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global Biologics and Biosimilars Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
5.2 Global Biologics and Biosimilars Sales by Type
5.2.1 Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global Biologics and Biosimilars Sales by Type (2019-2030) & (K Units)
5.2.3 Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
5.3 Global Biologics and Biosimilars Price by Type
6 BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
6.1 Global Biologics and Biosimilars Revenue by Application
6.1.1 Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global Biologics and Biosimilars Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
6.2 Global Biologics and Biosimilars Sales by Application
6.2.1 Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global Biologics and Biosimilars Sales by Application (2019-2030) & (K Units)
6.2.3 Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
6.3 Global Biologics and Biosimilars Price by Application
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Comapny Information
7.1.2 Roche Business Overview
7.1.3 Roche Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Roche Biologics and Biosimilars Product Portfolio
7.1.5 Roche Recent Developments
7.2 Amgen
7.2.1 Amgen Comapny Information
7.2.2 Amgen Business Overview
7.2.3 Amgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 Amgen Biologics and Biosimilars Product Portfolio
7.2.5 Amgen Recent Developments
7.3 AbbVie
7.3.1 AbbVie Comapny Information
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 AbbVie Biologics and Biosimilars Product Portfolio
7.3.5 AbbVie Recent Developments
7.4 Sanofi-Aventis
7.4.1 Sanofi-Aventis Comapny Information
7.4.2 Sanofi-Aventis Business Overview
7.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
7.4.5 Sanofi-Aventis Recent Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Comapny Information
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
7.5.5 Johnson & Johnson Recent Developments
7.6 Pfizer
7.6.1 Pfizer Comapny Information
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Pfizer Biologics and Biosimilars Product Portfolio
7.6.5 Pfizer Recent Developments
7.7 Novo Nordisk
7.7.1 Novo Nordisk Comapny Information
7.7.2 Novo Nordisk Business Overview
7.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
7.7.5 Novo Nordisk Recent Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Comapny Information
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
7.8.5 Eli Lilly Recent Developments
7.9 Novartis
7.9.1 Novartis Comapny Information
7.9.2 Novartis Business Overview
7.9.3 Novartis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.9.4 Novartis Biologics and Biosimilars Product Portfolio
7.9.5 Novartis Recent Developments
7.10 Merck
7.10.1 Merck Comapny Information
7.10.2 Merck Business Overview
7.10.3 Merck Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.10.4 Merck Biologics and Biosimilars Product Portfolio
7.10.5 Merck Recent Developments
7.11 3sbio
7.11.1 3sbio Comapny Information
7.11.2 3sbio Business Overview
7.11.3 3sbio Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.11.4 3sbio Biologics and Biosimilars Product Portfolio
7.11.5 3sbio Recent Developments
7.12 Changchun High Tech
7.12.1 Changchun High Tech Comapny Information
7.12.2 Changchun High Tech Business Overview
7.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
7.12.5 Changchun High Tech Recent Developments
7.13 CP Guojian
7.13.1 CP Guojian Comapny Information
7.13.2 CP Guojian Business Overview
7.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
7.13.5 CP Guojian Recent Developments
7.14 Biotech
7.14.1 Biotech Comapny Information
7.14.2 Biotech Business Overview
7.14.3 Biotech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.14.4 Biotech Biologics and Biosimilars Product Portfolio
7.14.5 Biotech Recent Developments
7.15 Gelgen
7.15.1 Gelgen Comapny Information
7.15.2 Gelgen Business Overview
7.15.3 Gelgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.15.4 Gelgen Biologics and Biosimilars Product Portfolio
7.15.5 Gelgen Recent Developments
7.16 Innovent
7.16.1 Innovent Comapny Information
7.16.2 Innovent Business Overview
7.16.3 Innovent Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.16.4 Innovent Biologics and Biosimilars Product Portfolio
7.16.5 Innovent Recent Developments
7.17 Dong Bao
7.17.1 Dong Bao Comapny Information
7.17.2 Dong Bao Business Overview
7.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
7.17.5 Dong Bao Recent Developments
7.18 Ganlee
7.18.1 Ganlee Comapny Information
7.18.2 Ganlee Business Overview
7.18.3 Ganlee Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.18.4 Ganlee Biologics and Biosimilars Product Portfolio
7.18.5 Ganlee Recent Developments
7.19 United Laboratories
7.19.1 United Laboratories Comapny Information
7.19.2 United Laboratories Business Overview
7.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
7.19.5 United Laboratories Recent Developments
8 NORTH AMERICA
8.1 North America Biologics and Biosimilars Market Size by Type
8.1.1 North America Biologics and Biosimilars Revenue by Type (2019-2030)
8.1.2 North America Biologics and Biosimilars Sales by Type (2019-2030)
8.1.3 North America Biologics and Biosimilars Price by Type (2019-2030)
8.2 North America Biologics and Biosimilars Market Size by Application
8.2.1 North America Biologics and Biosimilars Revenue by Application (2019-2030)
8.2.2 North America Biologics and Biosimilars Sales by Application (2019-2030)
8.2.3 North America Biologics and Biosimilars Price by Application (2019-2030)
8.3 North America Biologics and Biosimilars Market Size by Country
8.3.1 North America Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America Biologics and Biosimilars Price by Country (2019-2030)
8.3.4 U.S.
8.3.5 Canada
9 EUROPE
9.1 Europe Biologics and Biosimilars Market Size by Type
9.1.1 Europe Biologics and Biosimilars Revenue by Type (2019-2030)
9.1.2 Europe Biologics and Biosimilars Sales by Type (2019-2030)
9.1.3 Europe Biologics and Biosimilars Price by Type (2019-2030)
9.2 Europe Biologics and Biosimilars Market Size by Application
9.2.1 Europe Biologics and Biosimilars Revenue by Application (2019-2030)
9.2.2 Europe Biologics and Biosimilars Sales by Application (2019-2030)
9.2.3 Europe Biologics and Biosimilars Price by Application (2019-2030)
9.3 Europe Biologics and Biosimilars Market Size by Country
9.3.1 Europe Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe Biologics and Biosimilars Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 CHINA
10.1 China Biologics and Biosimilars Market Size by Type
10.1.1 China Biologics and Biosimilars Revenue by Type (2019-2030)
10.1.2 China Biologics and Biosimilars Sales by Type (2019-2030)
10.1.3 China Biologics and Biosimilars Price by Type (2019-2030)
10.2 China Biologics and Biosimilars Market Size by Application
10.2.1 China Biologics and Biosimilars Revenue by Application (2019-2030)
10.2.2 China Biologics and Biosimilars Sales by Application (2019-2030)
10.2.3 China Biologics and Biosimilars Price by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Biologics and Biosimilars Market Size by Type
11.1.1 Asia Biologics and Biosimilars Revenue by Type (2019-2030)
11.1.2 Asia Biologics and Biosimilars Sales by Type (2019-2030)
11.1.3 Asia Biologics and Biosimilars Price by Type (2019-2030)
11.2 Asia Biologics and Biosimilars Market Size by Application
11.2.1 Asia Biologics and Biosimilars Revenue by Application (2019-2030)
11.2.2 Asia Biologics and Biosimilars Sales by Application (2019-2030)
11.2.3 Asia Biologics and Biosimilars Price by Application (2019-2030)
11.3 Asia Biologics and Biosimilars Market Size by Country
11.3.1 Asia Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia Biologics and Biosimilars Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 MIDDLE EAST, AFRICA AND LATIN AMERICA
12.1 MEALA Biologics and Biosimilars Market Size by Type
12.1.1 MEALA Biologics and Biosimilars Revenue by Type (2019-2030)
12.1.2 MEALA Biologics and Biosimilars Sales by Type (2019-2030)
12.1.3 MEALA Biologics and Biosimilars Price by Type (2019-2030)
12.2 MEALA Biologics and Biosimilars Market Size by Application
12.2.1 MEALA Biologics and Biosimilars Revenue by Application (2019-2030)
12.2.2 MEALA Biologics and Biosimilars Sales by Application (2019-2030)
12.2.3 MEALA Biologics and Biosimilars Price by Application (2019-2030)
12.3 MEALA Biologics and Biosimilars Market Size by Country
12.3.1 MEALA Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA Biologics and Biosimilars Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 VALUE CHAIN AND SALES CHANNELS ANALYSIS
13.1 Biologics and Biosimilars Value Chain Analysis
13.1.1 Biologics and Biosimilars Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Biologics and Biosimilars Production Mode & Process
13.2 Biologics and Biosimilars Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Biologics and Biosimilars Distributors
13.2.3 Biologics and Biosimilars Customers
14 CONCLUDING INSIGHTS
15 APPENDIX
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
1.1 Product Definition
1.2 Biologics and Biosimilars Market by Type
1.2.1 Global Biologics and Biosimilars Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Biologics and Biosimilars Market by Application
1.3.1 Global Biologics and Biosimilars Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 BIOLOGICS AND BIOSIMILARS MARKET DYNAMICS
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 GLOBAL MARKET GROWTH PROSPECTS
3.1 Global Biologics and Biosimilars Revenue Estimates and Forecasts (2019-2030)
3.2 Global Biologics and Biosimilars Revenue by Region
3.2.1 Global Biologics and Biosimilars Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global Biologics and Biosimilars Revenue by Region (2019-2024)
3.2.3 Global Biologics and Biosimilars Revenue by Region (2025-2030)
3.2.4 Global Biologics and Biosimilars Revenue Market Share by Region (2019-2030)
3.3 Global Biologics and Biosimilars Sales Estimates and Forecasts 2019-2030
3.4 Global Biologics and Biosimilars Sales by Region
3.4.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global Biologics and Biosimilars Sales by Region (2019-2024)
3.4.3 Global Biologics and Biosimilars Sales by Region (2025-2030)
3.4.4 Global Biologics and Biosimilars Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
4.1 Global Biologics and Biosimilars Revenue by Manufacturers
4.1.1 Global Biologics and Biosimilars Revenue by Manufacturers (2019-2024)
4.1.2 Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global Biologics and Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global Biologics and Biosimilars Sales by Manufacturers
4.2.1 Global Biologics and Biosimilars Sales by Manufacturers (2019-2024)
4.2.2 Global Biologics and Biosimilars Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global Biologics and Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global Biologics and Biosimilars Sales Price by Manufacturers (2019-2024)
4.4 Global Biologics and Biosimilars Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Biologics and Biosimilars Manufacturers, Product Type & Application
4.7 Global Biologics and Biosimilars Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global Biologics and Biosimilars Market CR5 and HHI
4.8.2 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
5 BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
5.1 Global Biologics and Biosimilars Revenue by Type
5.1.1 Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global Biologics and Biosimilars Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
5.2 Global Biologics and Biosimilars Sales by Type
5.2.1 Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global Biologics and Biosimilars Sales by Type (2019-2030) & (K Units)
5.2.3 Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
5.3 Global Biologics and Biosimilars Price by Type
6 BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
6.1 Global Biologics and Biosimilars Revenue by Application
6.1.1 Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global Biologics and Biosimilars Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
6.2 Global Biologics and Biosimilars Sales by Application
6.2.1 Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global Biologics and Biosimilars Sales by Application (2019-2030) & (K Units)
6.2.3 Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
6.3 Global Biologics and Biosimilars Price by Application
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Comapny Information
7.1.2 Roche Business Overview
7.1.3 Roche Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Roche Biologics and Biosimilars Product Portfolio
7.1.5 Roche Recent Developments
7.2 Amgen
7.2.1 Amgen Comapny Information
7.2.2 Amgen Business Overview
7.2.3 Amgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 Amgen Biologics and Biosimilars Product Portfolio
7.2.5 Amgen Recent Developments
7.3 AbbVie
7.3.1 AbbVie Comapny Information
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 AbbVie Biologics and Biosimilars Product Portfolio
7.3.5 AbbVie Recent Developments
7.4 Sanofi-Aventis
7.4.1 Sanofi-Aventis Comapny Information
7.4.2 Sanofi-Aventis Business Overview
7.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
7.4.5 Sanofi-Aventis Recent Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Comapny Information
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
7.5.5 Johnson & Johnson Recent Developments
7.6 Pfizer
7.6.1 Pfizer Comapny Information
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Pfizer Biologics and Biosimilars Product Portfolio
7.6.5 Pfizer Recent Developments
7.7 Novo Nordisk
7.7.1 Novo Nordisk Comapny Information
7.7.2 Novo Nordisk Business Overview
7.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
7.7.5 Novo Nordisk Recent Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Comapny Information
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
7.8.5 Eli Lilly Recent Developments
7.9 Novartis
7.9.1 Novartis Comapny Information
7.9.2 Novartis Business Overview
7.9.3 Novartis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.9.4 Novartis Biologics and Biosimilars Product Portfolio
7.9.5 Novartis Recent Developments
7.10 Merck
7.10.1 Merck Comapny Information
7.10.2 Merck Business Overview
7.10.3 Merck Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.10.4 Merck Biologics and Biosimilars Product Portfolio
7.10.5 Merck Recent Developments
7.11 3sbio
7.11.1 3sbio Comapny Information
7.11.2 3sbio Business Overview
7.11.3 3sbio Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.11.4 3sbio Biologics and Biosimilars Product Portfolio
7.11.5 3sbio Recent Developments
7.12 Changchun High Tech
7.12.1 Changchun High Tech Comapny Information
7.12.2 Changchun High Tech Business Overview
7.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
7.12.5 Changchun High Tech Recent Developments
7.13 CP Guojian
7.13.1 CP Guojian Comapny Information
7.13.2 CP Guojian Business Overview
7.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
7.13.5 CP Guojian Recent Developments
7.14 Biotech
7.14.1 Biotech Comapny Information
7.14.2 Biotech Business Overview
7.14.3 Biotech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.14.4 Biotech Biologics and Biosimilars Product Portfolio
7.14.5 Biotech Recent Developments
7.15 Gelgen
7.15.1 Gelgen Comapny Information
7.15.2 Gelgen Business Overview
7.15.3 Gelgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.15.4 Gelgen Biologics and Biosimilars Product Portfolio
7.15.5 Gelgen Recent Developments
7.16 Innovent
7.16.1 Innovent Comapny Information
7.16.2 Innovent Business Overview
7.16.3 Innovent Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.16.4 Innovent Biologics and Biosimilars Product Portfolio
7.16.5 Innovent Recent Developments
7.17 Dong Bao
7.17.1 Dong Bao Comapny Information
7.17.2 Dong Bao Business Overview
7.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
7.17.5 Dong Bao Recent Developments
7.18 Ganlee
7.18.1 Ganlee Comapny Information
7.18.2 Ganlee Business Overview
7.18.3 Ganlee Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.18.4 Ganlee Biologics and Biosimilars Product Portfolio
7.18.5 Ganlee Recent Developments
7.19 United Laboratories
7.19.1 United Laboratories Comapny Information
7.19.2 United Laboratories Business Overview
7.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2019-2024)
7.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
7.19.5 United Laboratories Recent Developments
8 NORTH AMERICA
8.1 North America Biologics and Biosimilars Market Size by Type
8.1.1 North America Biologics and Biosimilars Revenue by Type (2019-2030)
8.1.2 North America Biologics and Biosimilars Sales by Type (2019-2030)
8.1.3 North America Biologics and Biosimilars Price by Type (2019-2030)
8.2 North America Biologics and Biosimilars Market Size by Application
8.2.1 North America Biologics and Biosimilars Revenue by Application (2019-2030)
8.2.2 North America Biologics and Biosimilars Sales by Application (2019-2030)
8.2.3 North America Biologics and Biosimilars Price by Application (2019-2030)
8.3 North America Biologics and Biosimilars Market Size by Country
8.3.1 North America Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America Biologics and Biosimilars Price by Country (2019-2030)
8.3.4 U.S.
8.3.5 Canada
9 EUROPE
9.1 Europe Biologics and Biosimilars Market Size by Type
9.1.1 Europe Biologics and Biosimilars Revenue by Type (2019-2030)
9.1.2 Europe Biologics and Biosimilars Sales by Type (2019-2030)
9.1.3 Europe Biologics and Biosimilars Price by Type (2019-2030)
9.2 Europe Biologics and Biosimilars Market Size by Application
9.2.1 Europe Biologics and Biosimilars Revenue by Application (2019-2030)
9.2.2 Europe Biologics and Biosimilars Sales by Application (2019-2030)
9.2.3 Europe Biologics and Biosimilars Price by Application (2019-2030)
9.3 Europe Biologics and Biosimilars Market Size by Country
9.3.1 Europe Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe Biologics and Biosimilars Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 CHINA
10.1 China Biologics and Biosimilars Market Size by Type
10.1.1 China Biologics and Biosimilars Revenue by Type (2019-2030)
10.1.2 China Biologics and Biosimilars Sales by Type (2019-2030)
10.1.3 China Biologics and Biosimilars Price by Type (2019-2030)
10.2 China Biologics and Biosimilars Market Size by Application
10.2.1 China Biologics and Biosimilars Revenue by Application (2019-2030)
10.2.2 China Biologics and Biosimilars Sales by Application (2019-2030)
10.2.3 China Biologics and Biosimilars Price by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Biologics and Biosimilars Market Size by Type
11.1.1 Asia Biologics and Biosimilars Revenue by Type (2019-2030)
11.1.2 Asia Biologics and Biosimilars Sales by Type (2019-2030)
11.1.3 Asia Biologics and Biosimilars Price by Type (2019-2030)
11.2 Asia Biologics and Biosimilars Market Size by Application
11.2.1 Asia Biologics and Biosimilars Revenue by Application (2019-2030)
11.2.2 Asia Biologics and Biosimilars Sales by Application (2019-2030)
11.2.3 Asia Biologics and Biosimilars Price by Application (2019-2030)
11.3 Asia Biologics and Biosimilars Market Size by Country
11.3.1 Asia Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia Biologics and Biosimilars Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 MIDDLE EAST, AFRICA AND LATIN AMERICA
12.1 MEALA Biologics and Biosimilars Market Size by Type
12.1.1 MEALA Biologics and Biosimilars Revenue by Type (2019-2030)
12.1.2 MEALA Biologics and Biosimilars Sales by Type (2019-2030)
12.1.3 MEALA Biologics and Biosimilars Price by Type (2019-2030)
12.2 MEALA Biologics and Biosimilars Market Size by Application
12.2.1 MEALA Biologics and Biosimilars Revenue by Application (2019-2030)
12.2.2 MEALA Biologics and Biosimilars Sales by Application (2019-2030)
12.2.3 MEALA Biologics and Biosimilars Price by Application (2019-2030)
12.3 MEALA Biologics and Biosimilars Market Size by Country
12.3.1 MEALA Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA Biologics and Biosimilars Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 VALUE CHAIN AND SALES CHANNELS ANALYSIS
13.1 Biologics and Biosimilars Value Chain Analysis
13.1.1 Biologics and Biosimilars Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Biologics and Biosimilars Production Mode & Process
13.2 Biologics and Biosimilars Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Biologics and Biosimilars Distributors
13.2.3 Biologics and Biosimilars Customers
14 CONCLUDING INSIGHTS
15 APPENDIX
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
LIST OF TABLES
Table 1. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Monoclonal Antibodies Major Manufacturers
Table 3. Interferon Major Manufacturers
Table 4. Erythropoietin Major Manufacturers
Table 5. Insulin Major Manufacturers
Table 6. Vaccines Major Manufacturers
Table 7. Others Major Manufacturers
Table 8. Global Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 9. Tumor Major Manufacturers
Table 10. Diabetes Major Manufacturers
Table 11. Cardiovascular Major Manufacturers
Table 12. Hemophilia Major Manufacturers
Table 13. Others Major Manufacturers
Table 14. Biologics and Biosimilars Industry Trends
Table 15. Biologics and Biosimilars Industry Drivers
Table 16. Biologics and Biosimilars Industry Opportunities and Challenges
Table 17. Biologics and Biosimilars Industry Restraints
Table 18. Global Biologics and Biosimilars Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Biologics and Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 20. Global Biologics and Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 21. Global Biologics and Biosimilars Revenue Market Share by Region (2019-2024)
Table 22. Global Biologics and Biosimilars Revenue Market Share by Region (2025-2030)
Table 23. Global Biologics and Biosimilars Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
Table 24. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
Table 25. Global Biologics and Biosimilars Sales by Region (2025-2030) & (K Units)
Table 26. Global Biologics and Biosimilars Sales Market Share by Region (2019-2024)
Table 27. Global Biologics and Biosimilars Sales Market Share by Region (2025-2030)
Table 28. Global Biologics and Biosimilars Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 29. Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2019-2024)
Table 30. Global Biologics and Biosimilars Sales by Manufacturers (US$ Million) & (2019-2024)
Table 31. Global Biologics and Biosimilars Sales Market Share by Manufacturers (2019-2024)
Table 32. Global Biologics and Biosimilars Sales Price (USD/Unit) of Manufacturers (2019-2024)
Table 33. Global Biologics and Biosimilars Key Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 34. Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
Table 35. Global Biologics and Biosimilars Manufacturers, Product Type & Application
Table 36. Global Biologics and Biosimilars Manufacturers Commercialization Time
Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 38. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 39. Global Biologics and Biosimilars Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 40. Global Biologics and Biosimilars Revenue by Type (2019-2024) & (US$ Million)
Table 41. Global Biologics and Biosimilars Revenue by Type (2025-2030) & (US$ Million)
Table 42. Global Biologics and Biosimilars Revenue Market Share by Type (2019-2024)
Table 43. Global Biologics and Biosimilars Revenue Market Share by Type (2025-2030)
Table 44. Global Biologics and Biosimilars Sales by Type 2019 VS 2023 VS 2030 (K Units)
Table 45. Global Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 46. Global Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 47. Global Biologics and Biosimilars Sales Market Share by Type (2019-2024)
Table 48. Global Biologics and Biosimilars Sales Market Share by Type (2025-2030)
Table 49. Global Biologics and Biosimilars Price by Type (2019-2024) & (USD/Unit)
Table 50. Global Biologics and Biosimilars Price by Type (2025-2030) & (USD/Unit)
Table 51. Global Biologics and Biosimilars Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 52. Global Biologics and Biosimilars Revenue by Application (2019-2024) & (US$ Million)
Table 53. Global Biologics and Biosimilars Revenue by Application (2025-2030) & (US$ Million)
Table 54. Global Biologics and Biosimilars Revenue Market Share by Application (2019-2024)
Table 55. Global Biologics and Biosimilars Revenue Market Share by Application (2025-2030)
Table 56. Global Biologics and Biosimilars Sales by Application 2019 VS 2023 VS 2030 (K Units)
Table 57. Global Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 58. Global Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 59. Global Biologics and Biosimilars Sales Market Share by Application (2019-2024)
Table 60. Global Biologics and Biosimilars Sales Market Share by Application (2025-2030)
Table 61. Global Biologics and Biosimilars Price by Application (2019-2024) & (USD/Unit)
Table 62. Global Biologics and Biosimilars Price by Application (2025-2030) & (USD/Unit)
Table 63. Roche Company Information
Table 64. Roche Business Overview
Table 65. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 66. Roche Biologics and Biosimilars Product Portfolio
Table 67. Roche Recent Development
Table 68. Amgen Company Information
Table 69. Amgen Business Overview
Table 70. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 71. Amgen Biologics and Biosimilars Product Portfolio
Table 72. Amgen Recent Development
Table 73. AbbVie Company Information
Table 74. AbbVie Business Overview
Table 75. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 76. AbbVie Biologics and Biosimilars Product Portfolio
Table 77. AbbVie Recent Development
Table 78. Sanofi-Aventis Company Information
Table 79. Sanofi-Aventis Business Overview
Table 80. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 82. Sanofi-Aventis Recent Development
Table 83. Johnson & Johnson Company Information
Table 84. Johnson & Johnson Business Overview
Table 85. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 87. Johnson & Johnson Recent Development
Table 88. Pfizer Company Information
Table 89. Pfizer Business Overview
Table 90. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. Pfizer Biologics and Biosimilars Product Portfolio
Table 92. Pfizer Recent Development
Table 93. Novo Nordisk Company Information
Table 94. Novo Nordisk Business Overview
Table 95. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 97. Novo Nordisk Recent Development
Table 98. Eli Lilly Company Information
Table 99. Eli Lilly Business Overview
Table 100. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 102. Eli Lilly Recent Development
Table 103. Novartis Company Information
Table 104. Novartis Business Overview
Table 105. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. Novartis Biologics and Biosimilars Product Portfolio
Table 107. Novartis Recent Development
Table 108. Merck Company Information
Table 109. Merck Business Overview
Table 110. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Merck Biologics and Biosimilars Product Portfolio
Table 112. Merck Recent Development
Table 113. 3sbio Company Information
Table 114. 3sbio Business Overview
Table 115. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. 3sbio Biologics and Biosimilars Product Portfolio
Table 117. 3sbio Recent Development
Table 118. Changchun High Tech Company Information
Table 119. Changchun High Tech Business Overview
Table 120. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 122. Changchun High Tech Recent Development
Table 123. CP Guojian Company Information
Table 124. CP Guojian Business Overview
Table 125. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. CP Guojian Biologics and Biosimilars Product Portfolio
Table 127. CP Guojian Recent Development
Table 128. Biotech Company Information
Table 129. Biotech Business Overview
Table 130. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 131. Biotech Biologics and Biosimilars Product Portfolio
Table 132. Biotech Recent Development
Table 133. Gelgen Company Information
Table 134. Gelgen Business Overview
Table 135. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 136. Gelgen Biologics and Biosimilars Product Portfolio
Table 137. Gelgen Recent Development
Table 138. Innovent Company Information
Table 139. Innovent Business Overview
Table 140. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 141. Innovent Biologics and Biosimilars Product Portfolio
Table 142. Innovent Recent Development
Table 143. Dong Bao Company Information
Table 144. Dong Bao Business Overview
Table 145. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 146. Dong Bao Biologics and Biosimilars Product Portfolio
Table 147. Dong Bao Recent Development
Table 148. Ganlee Company Information
Table 149. Ganlee Business Overview
Table 150. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 151. Ganlee Biologics and Biosimilars Product Portfolio
Table 152. Ganlee Recent Development
Table 153. United Laboratories Company Information
Table 154. United Laboratories Business Overview
Table 155. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 156. United Laboratories Biologics and Biosimilars Product Portfolio
Table 157. United Laboratories Recent Development
Table 158. North America Biologics and Biosimilars Revenue by Type (2019-2024) & (US$ Million)
Table 159. North America Biologics and Biosimilars Revenue by Type (2025-2030) & (US$ Million)
Table 160. North America Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 161. North America Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 162. North America Biologics and Biosimilars Sales Price by Type (2019-2024) & (USD/Unit)
Table 163. North America Biologics and Biosimilars Sales Price by Type (2025-2030) & (USD/Unit)
Table 164. North America Biologics and Biosimilars Revenue by Application (2019-2024) & (US$ Million)
Table 165. North America Biologics and Biosimilars Revenue by Application (2025-2030) & (US$ Million)
Table 166. North America Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 167. North America Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 168. North America Biologics and Biosimilars Sales Price by Application (2019-2024) & (USD/Unit)
Table 169. North America Biologics and Biosimilars Sales Price by Application (2025-2030) & (USD/Unit)
Table 170. North America Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 171. North America Biologics and Biosimilars Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 172. North America Biologics and Biosimilars Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 173. North America Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030) & (K Units)
Table 174. North America Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 175. North America Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 176. North America Biologics and Biosimilars Sales Price by Country (2019-2024) & (USD/Unit)
Table 177. North America Biologics and Biosimilars Sales Price by Country (2025-2030) & (USD/Unit)
Table 178. US Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Table 179. Canada Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Table 180. Europe Biologics and Biosimilars Revenue by Type (2019-2024) & (US$ Million)
Table 181. Europe Biologics and Biosimilars Revenue by Type (2025-2030) & (US$ Million)
Table 182. Europe Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 183. Europe Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 184. Europe Biologics and Biosimilars Sales Price by Type (2019-2024) & (USD/Unit)
Table 185. Europe Biologics and Biosimilars Sales Price by Type (2025-2030) & (USD/Unit)
Table 186. Europe Biologics and Biosimilars Revenue by Application (2019-2024) & (US$ Million)
Table 187. Europe Biologics and Biosimilars Revenue by Application (2025-2030) & (US$ Million)
Table 188. Europe Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 189. Europe Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 190. Europe Biologics and Biosimilars Sales Price by Application (2019-2024) & (USD/Unit)
Table 191. Europe Biologics and Biosimilars Sales Price by Application (2025-2030) & (USD/Unit)
Table 192. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 193. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 194. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 195. Europe Biologics and Biosimilars Sales by Country (20
Table 1. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Monoclonal Antibodies Major Manufacturers
Table 3. Interferon Major Manufacturers
Table 4. Erythropoietin Major Manufacturers
Table 5. Insulin Major Manufacturers
Table 6. Vaccines Major Manufacturers
Table 7. Others Major Manufacturers
Table 8. Global Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 9. Tumor Major Manufacturers
Table 10. Diabetes Major Manufacturers
Table 11. Cardiovascular Major Manufacturers
Table 12. Hemophilia Major Manufacturers
Table 13. Others Major Manufacturers
Table 14. Biologics and Biosimilars Industry Trends
Table 15. Biologics and Biosimilars Industry Drivers
Table 16. Biologics and Biosimilars Industry Opportunities and Challenges
Table 17. Biologics and Biosimilars Industry Restraints
Table 18. Global Biologics and Biosimilars Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Biologics and Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 20. Global Biologics and Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 21. Global Biologics and Biosimilars Revenue Market Share by Region (2019-2024)
Table 22. Global Biologics and Biosimilars Revenue Market Share by Region (2025-2030)
Table 23. Global Biologics and Biosimilars Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
Table 24. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
Table 25. Global Biologics and Biosimilars Sales by Region (2025-2030) & (K Units)
Table 26. Global Biologics and Biosimilars Sales Market Share by Region (2019-2024)
Table 27. Global Biologics and Biosimilars Sales Market Share by Region (2025-2030)
Table 28. Global Biologics and Biosimilars Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 29. Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2019-2024)
Table 30. Global Biologics and Biosimilars Sales by Manufacturers (US$ Million) & (2019-2024)
Table 31. Global Biologics and Biosimilars Sales Market Share by Manufacturers (2019-2024)
Table 32. Global Biologics and Biosimilars Sales Price (USD/Unit) of Manufacturers (2019-2024)
Table 33. Global Biologics and Biosimilars Key Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 34. Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
Table 35. Global Biologics and Biosimilars Manufacturers, Product Type & Application
Table 36. Global Biologics and Biosimilars Manufacturers Commercialization Time
Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 38. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 39. Global Biologics and Biosimilars Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 40. Global Biologics and Biosimilars Revenue by Type (2019-2024) & (US$ Million)
Table 41. Global Biologics and Biosimilars Revenue by Type (2025-2030) & (US$ Million)
Table 42. Global Biologics and Biosimilars Revenue Market Share by Type (2019-2024)
Table 43. Global Biologics and Biosimilars Revenue Market Share by Type (2025-2030)
Table 44. Global Biologics and Biosimilars Sales by Type 2019 VS 2023 VS 2030 (K Units)
Table 45. Global Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 46. Global Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 47. Global Biologics and Biosimilars Sales Market Share by Type (2019-2024)
Table 48. Global Biologics and Biosimilars Sales Market Share by Type (2025-2030)
Table 49. Global Biologics and Biosimilars Price by Type (2019-2024) & (USD/Unit)
Table 50. Global Biologics and Biosimilars Price by Type (2025-2030) & (USD/Unit)
Table 51. Global Biologics and Biosimilars Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 52. Global Biologics and Biosimilars Revenue by Application (2019-2024) & (US$ Million)
Table 53. Global Biologics and Biosimilars Revenue by Application (2025-2030) & (US$ Million)
Table 54. Global Biologics and Biosimilars Revenue Market Share by Application (2019-2024)
Table 55. Global Biologics and Biosimilars Revenue Market Share by Application (2025-2030)
Table 56. Global Biologics and Biosimilars Sales by Application 2019 VS 2023 VS 2030 (K Units)
Table 57. Global Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 58. Global Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 59. Global Biologics and Biosimilars Sales Market Share by Application (2019-2024)
Table 60. Global Biologics and Biosimilars Sales Market Share by Application (2025-2030)
Table 61. Global Biologics and Biosimilars Price by Application (2019-2024) & (USD/Unit)
Table 62. Global Biologics and Biosimilars Price by Application (2025-2030) & (USD/Unit)
Table 63. Roche Company Information
Table 64. Roche Business Overview
Table 65. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 66. Roche Biologics and Biosimilars Product Portfolio
Table 67. Roche Recent Development
Table 68. Amgen Company Information
Table 69. Amgen Business Overview
Table 70. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 71. Amgen Biologics and Biosimilars Product Portfolio
Table 72. Amgen Recent Development
Table 73. AbbVie Company Information
Table 74. AbbVie Business Overview
Table 75. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 76. AbbVie Biologics and Biosimilars Product Portfolio
Table 77. AbbVie Recent Development
Table 78. Sanofi-Aventis Company Information
Table 79. Sanofi-Aventis Business Overview
Table 80. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 82. Sanofi-Aventis Recent Development
Table 83. Johnson & Johnson Company Information
Table 84. Johnson & Johnson Business Overview
Table 85. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 87. Johnson & Johnson Recent Development
Table 88. Pfizer Company Information
Table 89. Pfizer Business Overview
Table 90. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. Pfizer Biologics and Biosimilars Product Portfolio
Table 92. Pfizer Recent Development
Table 93. Novo Nordisk Company Information
Table 94. Novo Nordisk Business Overview
Table 95. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 97. Novo Nordisk Recent Development
Table 98. Eli Lilly Company Information
Table 99. Eli Lilly Business Overview
Table 100. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 102. Eli Lilly Recent Development
Table 103. Novartis Company Information
Table 104. Novartis Business Overview
Table 105. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. Novartis Biologics and Biosimilars Product Portfolio
Table 107. Novartis Recent Development
Table 108. Merck Company Information
Table 109. Merck Business Overview
Table 110. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Merck Biologics and Biosimilars Product Portfolio
Table 112. Merck Recent Development
Table 113. 3sbio Company Information
Table 114. 3sbio Business Overview
Table 115. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. 3sbio Biologics and Biosimilars Product Portfolio
Table 117. 3sbio Recent Development
Table 118. Changchun High Tech Company Information
Table 119. Changchun High Tech Business Overview
Table 120. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 122. Changchun High Tech Recent Development
Table 123. CP Guojian Company Information
Table 124. CP Guojian Business Overview
Table 125. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. CP Guojian Biologics and Biosimilars Product Portfolio
Table 127. CP Guojian Recent Development
Table 128. Biotech Company Information
Table 129. Biotech Business Overview
Table 130. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 131. Biotech Biologics and Biosimilars Product Portfolio
Table 132. Biotech Recent Development
Table 133. Gelgen Company Information
Table 134. Gelgen Business Overview
Table 135. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 136. Gelgen Biologics and Biosimilars Product Portfolio
Table 137. Gelgen Recent Development
Table 138. Innovent Company Information
Table 139. Innovent Business Overview
Table 140. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 141. Innovent Biologics and Biosimilars Product Portfolio
Table 142. Innovent Recent Development
Table 143. Dong Bao Company Information
Table 144. Dong Bao Business Overview
Table 145. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 146. Dong Bao Biologics and Biosimilars Product Portfolio
Table 147. Dong Bao Recent Development
Table 148. Ganlee Company Information
Table 149. Ganlee Business Overview
Table 150. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 151. Ganlee Biologics and Biosimilars Product Portfolio
Table 152. Ganlee Recent Development
Table 153. United Laboratories Company Information
Table 154. United Laboratories Business Overview
Table 155. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 156. United Laboratories Biologics and Biosimilars Product Portfolio
Table 157. United Laboratories Recent Development
Table 158. North America Biologics and Biosimilars Revenue by Type (2019-2024) & (US$ Million)
Table 159. North America Biologics and Biosimilars Revenue by Type (2025-2030) & (US$ Million)
Table 160. North America Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 161. North America Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 162. North America Biologics and Biosimilars Sales Price by Type (2019-2024) & (USD/Unit)
Table 163. North America Biologics and Biosimilars Sales Price by Type (2025-2030) & (USD/Unit)
Table 164. North America Biologics and Biosimilars Revenue by Application (2019-2024) & (US$ Million)
Table 165. North America Biologics and Biosimilars Revenue by Application (2025-2030) & (US$ Million)
Table 166. North America Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 167. North America Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 168. North America Biologics and Biosimilars Sales Price by Application (2019-2024) & (USD/Unit)
Table 169. North America Biologics and Biosimilars Sales Price by Application (2025-2030) & (USD/Unit)
Table 170. North America Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 171. North America Biologics and Biosimilars Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 172. North America Biologics and Biosimilars Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 173. North America Biologics and Biosimilars Sales by Country (2019 VS 2023 VS 2030) & (K Units)
Table 174. North America Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 175. North America Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 176. North America Biologics and Biosimilars Sales Price by Country (2019-2024) & (USD/Unit)
Table 177. North America Biologics and Biosimilars Sales Price by Country (2025-2030) & (USD/Unit)
Table 178. US Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Table 179. Canada Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Table 180. Europe Biologics and Biosimilars Revenue by Type (2019-2024) & (US$ Million)
Table 181. Europe Biologics and Biosimilars Revenue by Type (2025-2030) & (US$ Million)
Table 182. Europe Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 183. Europe Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 184. Europe Biologics and Biosimilars Sales Price by Type (2019-2024) & (USD/Unit)
Table 185. Europe Biologics and Biosimilars Sales Price by Type (2025-2030) & (USD/Unit)
Table 186. Europe Biologics and Biosimilars Revenue by Application (2019-2024) & (US$ Million)
Table 187. Europe Biologics and Biosimilars Revenue by Application (2025-2030) & (US$ Million)
Table 188. Europe Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 189. Europe Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 190. Europe Biologics and Biosimilars Sales Price by Application (2019-2024) & (USD/Unit)
Table 191. Europe Biologics and Biosimilars Sales Price by Application (2025-2030) & (USD/Unit)
Table 192. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 193. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 194. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 195. Europe Biologics and Biosimilars Sales by Country (20
